Kolexia
Luycx Odile Médecine générale
Luycx Odile
Médecine générale
Hôpital du Scorff
Lorient, France
35 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Myélome multiple Anémie Tumeurs à plasmocytes Exanthème Neutropénie Leucémie myéloïde chronique BCR-ABL positive Thrombopénie Aberrations des chromosomes Leucémies

Collaborateurs

Voir plus
Niault Mathilde
Niault Mathilde
Hôpital du Scorff, Lorient, France
Le Coz Marie-Francoise
Le Coz Marie-Francoise
Hôpital du Scorff, Lorient, France
Trebouet Adrien
Trebouet Adrien
Hôpital du Scorff, Lorient, France
Norwood James
Norwood James
Hôpital du Scorff, Lorient, France

Industries

Voir plus
Janssen
4 collaboration(s)
Dernière en 2022
Amgen
1 collaboration(s)
Dernière en 2021
Takeda Pharmaceutical
1 collaboration(s)
Dernière en 2022
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

Voir plus
A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma: A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral Ixazomib (MLN9708) Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Essai Clinique (Takeda Pharmaceutical)   07 février 2023
What Is the Benefit of Autologous Stem Cell Transplantation in Multiple Myeloma Beyond the Age of 65? Inputs from Real-World Data in the Emmy Cohort
Annual Meeting Abstracts 2022   15 novembre 2022
Treatment emergent peripheral neuropathy in the CASSIOPEIA trial.
Haematologica   01 juillet 2022
Switches of tyrosine-kinase inhibitors in chronic phase of chronic myeloid leukemia in real life.
American journal of hematology   30 septembre 2018
CD200 expression in flow cytometry helps to distinguish mantle cell lymphoma from other CD5-positive B-cell neoplasms.
Hematological oncology   15 avril 2018
Outcome of Ph negative myeloproliferative neoplasms transforming to accelerated or leukemic phase.
Leukemia & lymphoma   04 avril 2018
Emergence and evolution of mutations are key features of disease progression in myelodysplastic patients with lower-risk del(5q) treated with lenalidomide.
Haematologica   21 décembre 2017
Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma.
Blood   11 octobre 2016
VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial.
Blood   21 mars 2016
Bortezomib, Thalidomide and Dexamethasone (VTD) Is Superior to Bortezomib, Cyclophosphamide and Dexamethasone (VCD) Prior to Autologous Stem Cell Transplantation for Patients with De Novo Multiple Myeloma. Results of the Prospective IFM 2013-04 Trial
Blood   03 décembre 2015